BioXcel Therapeutics (BTAI) Capital Expenditures (2018 - 2022)

BioXcel Therapeutics' Capital Expenditures history runs 5 years deep, the most recent figure standing at $19000.0 for Q2 2022.

• On a quarterly basis, Capital Expenditures fell 81.0% year-over-year to $19000.0 in Q2 2022; TTM through Sep 2023 was $19000.0, a 106.99% increase from a year earlier, with the FY2023 full-year figure at $20000.0, down 85.61% from the prior year.
• Capital Expenditures slipped to $19000.0 in Q2 2022 per BTAI's latest filing, from $120000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $600000.0 in Q1 2019 and bottomed at -$411000.0 in Q4 2021.
• The 5-year median for Capital Expenditures is $52500.0 (2018), against an average of $97937.5.
• Across the five-year window, Capital Expenditures soared 13400.0% in 2020 and slumped 252.22% in 2021, its largest moves.
• Year by year, Capital Expenditures stood at $158000.0 in 2018, then plunged by 98.73% to $2000.0 in 2019, then surged by 13400.0% to $270000.0 in 2020, then slumped by 252.22% to -$411000.0 in 2021, then surged by 104.62% to $19000.0 in 2022.
• Per Business Quant, the three latest BTAI Capital Expenditures figures stand at $19000.0 (Q2 2022), $120000.0 (Q1 2022), and -$411000.0 (Q4 2021).